Autopsy report · NCT01202890
Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer
Cause of deathSlow enrollment
“Terminated due to inadequate rate of accrual.”
Life of this trial
- Ran for about 1 year 8 months before it stopped.
- 1 participant enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- New Mexico Cancer Research Alliance
- Sponsor type
- University, hospital or other
- Conditions
- Ovarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Carcinoma; Primary Peritoneal Carcinoma
- Interventions
- Lenalidomide, Liposomal Doxorubicin, Bevacizumab; Revlimid, Doxil, Avastin
- Participants
- 1
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Evaluating the Effects of an Exercise Intervention on the Gut Microbiota in Stage II-III Colorectal Cancer Survivors
“Terminated due to low accrual.” - Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)
“Terminated due to poor accrual” - Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer
“Terminated prematurely due to low accrual.” - eHealth Diet and Physical Activity Program for the Improvement of Health in Rural Latino Cancer Survivors
“Terminated due to slow accrual.” - Efficacy and Safety of Salkera Emollient Foam in the Treatment of Moderate to Severe Keratosis Pilaris, a Prospective Study
“terminated due to administrative reasons.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.